Performance and Use of a Ribonucleotide Reductase Herpes Simplex Virus Type-Specific Serological Assay

Clinical and Diagnostic Laboratory Immunology

Volumn 11, Issue 1, 2004, Pages 42-49

  Wales, S Q ^a,b   Smith, C C ^b   Wachsman, M ^a   Calton, G ^a   Aurelian, L ^b  

^a AuRx Inc   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AU 1 PEPTIDE; AU 2 PEPTIDE; EPITOPE; R1 PEPTIDE ANTIGEN; RIBONUCLEOTIDE REDUCTASE; THROMBOSPONDIN; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS ENZYME;

ANIMAL CELL; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 2; HERPES VIRUS INFECTION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; SERODIAGNOSIS; STANDARD; WESTERN BLOTTING;

BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HERPES GENITALIS; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HUMANS; RIBONUCLEOTIDE REDUCTASES; SEROLOGIC TESTS;

EID: 0347128375     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/CDLI.11.1.42-49.2004     Document Type: Article

References (65)

1. Armstrong, G. L., J. Schillinger, L. Markowitz, A. J. Nahmias, R. E. Johnson, G. M. McQuillan, and M. E. St. Louis. 2001. Incidence of herpes simplex virus type 2 infection in the United States. Am. J. Epidemiol. 153:912-920.
2. Ashley, R. L., and A. Wald. 1999. Genital herpes: review of the epidemic and potential use of type-specific serology. Clin. Microbiol. Rev. 12:1-8.
3. Ashley, R. L., M. Eagleton, and N. Pfeiffer. 1999. Ability of a rapid serology test to detect seroconversion to herpes simplex virus type 2 glycoprotein G soon after infection. J. Clin. Microbiol. 37:1632-1633.
4. Ashley, R. L. 2002. Performance and use of HSV type-specific serology test kits. Herpes 9:38-45.
5. Aurelian, L. 1998. Herpes simplex virus type 2: unique biological properties include neoplastic potential mediated by the PK domain of the large subunit of ribonucleotide reductase. Front. Biosci. 3:237-249.
6. Aurelian, L. 2000. Herpes simplex viruses, p. 384-409. In S. Specter, R. L. Hodinka, S. A. Young (ed.), Clinical virology manual, 3rd cd. ASM Press, Washington, D.C.
7. Aurelian, L. (ed). 1990. Herpesviruses, the immune system and AIDS. Developments in medical virology 6. Kluwer Academic Publishers, Boston, Mass.
8. Aurelian, L., and C. C. Smith. 2000. Herpes simplex virus type 2 growth and latency reactivation by co-cultivation are inhibited with antisense oligonucleotides complementary to the translation initiation site of the large subunit of ribonucleotide reductase (RR1). Antisense Nucleic Acid Drug Dev. 10:77-85.
9. Aurelian, L., P. Terzano, C. C. Smith, T. D. Chung, A. Shamsuddin, S. Costa, and C. Orlandi. 1989. Amino terminal epitope of herpes simplex virus type 2 ICP10 protein as a molecular diagnostic marker for cervical intraepithelial neoplasia. Cancer Cells 7:187-191.
10. Aurelian, L., S. Yasumoto, and C. C. Smith. 1988. Antigen-specific immune suppressor factor in herpes simplex virus type 2 infections of UVB-irradiated mice. J. Virol. 62:2520-2524.
11. Bapat, A. R., S. P. Grill, L. M. Nutter, and Y.-C. Cheng. 1987. Study of ribonucleotide reductase in cells infected with six clinical isolates of herpes simplex virus type 2 (HSV-2) with mutations in its larger subunit. Virology 161:249-251.
12. Bergstrom, T., A. Vahlne, K. Alestig, S. Jeansson, M. Forsgren, and E. Lycke. 1990. Primary and recurrent herpes simplex virus type 2-induced meningitis. J. Infect. Dis. 162:322-330.
13. Bernstein, D. L., M. A. Lovett, and Y. J. Bryson. 1984. The effects of acyclovir on antibody response to herpes simplex virus in primary genital herpetic infections. J. Infect. Dis. 150:7-13.
14. Chung, T. D., J. Luo, J. P. Wymer, C. C. Smith, and L. Aurelian. 1991. Leucinc repeats in the large subunit of herpes simplex virus type 2 (HSV-2) ribonucleotide reductase (ICP10) are involved in RR activity and subunit complex formation. J. Gen. Virol. 72:1139-1144.
15. Corey, L. 2002. Challenges in genital herpes simplex virus management. J. Infect. Dis. 186:S29-S33.
16. Cowan, F. M. 2000. Testing for type-specific antibody to herpes simplex virus-implications for clinical practice. J. Antimicrob. Chemother. 45:S9-S13.
17. Dawson, G. J., K. H. Chau, C. M. Cabal, P. O. Yarbough, G. R. Reyes, and I. K. Mushahwar. 1992. Solid phase enzyme-linked immunosorbent assay for hepatitis E virus IgG and IgM antibodies utilizing recombinant antigens and synthetic peptides. J. Virol. Methods 38:175-186.
18. Dennett, C., G. M. Cleator, and P. E. Klapper. 1997. HSV-1 and HSV-2 in herpes simplex encephalitis: a study of sixty-four cases in the United Kingdom. J. Med. Virol. 53:1-3.
19. Dolan, A., F. E. Jamieson, C. Cunningham, B. C. Barnett, and D. J. McGeogh. 1998. The genome sequence of herpes simplex virus type 2. J. Virol. 72:2010-2021.
20. Eing, B. R., L. Lippelt, E. U. Lorentzen, W. Hafezi, W. Schlumberger, K. Steinhagen, and J. E. Kuhn. 2002. Evaluation of confirmatory strategies for detection of type-specific antibodies against herpes simplex virus type 2. J. Clin. Microbiol. 40:407-413.
21. Eis-Hubinger, A. M., M. Daumer, B. Matz, and K. E. Schneweis. 1999. Evaluation of three glycoprotein G2-based enzyme immunoassays for detection of antibodies to herpes simplex virus type 2 in human sera. J. Clin. Microbiol. 37:1242-1246.
22. Feldman, L. T., A. R. Ellison, C. C. Voytek, L. Yang, P. Krause, and T. P. Margolis. 2002. Spontaneous molecular reactivation of herpes simplex virus type 1 latency in mice. Proc. Natl. Acad. Sci. USA 99:978-983.
23. Field, R. R., D. W. T. Ho, W. L. Irving, I. D. Isaacs, and A. C. Cunningham. 1993. The reliability of serological tests for the diagnosis of genital herpes: a critique. Pathology 25:175-179.
24. Fisman, D. N., M. Lipsitch, E. W. Hook III, and S. J. Goldie. 2002. Projection of the future dimensions and costs of the genital herpes simplex type 2 epidemic in the United States. Sex. Transm. Dis. 29:608-622.
25. Gopal, R., T. Gibbs, M. J. Slomka, J. Whitworth, L. M. Carpenter, A. Vyse, and D. W. Brown. 2000. A monoclonal blocking EIA for herpes simplex virus type 2 antibody: validation for seroepidemiological studies in Africa. J. Virol. Methods 87:71-80.
26. Gottlieb, S. L., J. M. Douglas, Jr., D. S. Schmid, G. Bolan, M. latesta, C. K. Malotte, J. Zenilman, M. Foster, A. E. Barón, J. F. Steiner, T. A. Peterman, M. L. Kamb, et al. 2002. Seroprevalence and correlates of herpes simplex virus type 2 infection in five sexually transmitted-disease clinics. J. Infect. Dis. 186:1381-1389.
27. Grabowska, A., C. Jameson, P. Laing, S. Jeansson, E. Sjogren-Jansson, J. Taylor, A. Cunningham, and W. L. Irving. 1999. Identification of type-specific domains within glycoprotein G of herpes simplex virus type 2 (HSV-2) recognized by the majority of patients infected with HSV-2, but not by those infected with HSV-1. J. Gen. Virol. 80:1789-1798.
28. Hashido, M., F. K. Lee, S. Inouye, and T. Kawana. 1997. Detection of herpes simplex virus type specific antibodies by an enzyme-linked immunosorbent assay based on glycoprotein G. J. Med. Virol. 53:319-323.
29. Ho, D. W., P. R. Field, W. L. Irving, D. R. Packham, and A. L. Cunningham. 1993. Detection of immunoglobulin M antibodies to glycoprotein G-2 by Western blot (immunoblot) for diagnosis of initial herpes simplex virus type 2 genital infections. J. Clin. Microbiol. 31:3157-3164.
30. Hogrefe, W., X. Su, J. Song, R. Ashley, and L. Kong. 2002. Detection of herpes simplex virus type 2-specific immunoglobulin G antibodies in African sera by using recombinant gG2 Western blotting and gG2 inhibition. J. Clin. Microbiol. 40:3635-3640.
31. Ikoma, M., J.-A. Liljeqvist, J. Groen, K. L. Glazenburg, T. T. Hauw, and S. Welling-Wester. 2002. Use of a fragment of glycoprotein G-2 produced in the baculovirus expression system for detecting herpes simplex virus type 2-specific antibodies. J. Clin. Microbiol. 40:2526-2532.
32. Kleinschmidt-Demasters, B. K., and D. H. Gilden. 2001. The expanding spectrum of herpesvirus infections of the nervous system. Brain Pathol. 11:440-451.
33. Koutsky, L. A., R. L. Ashley, K. K. Holmes, C. E. Stevens, C. W. Critchlow, N. Kiviat, C. M. Lipinski, P. Wolner-Hanssen, and L. Corey. 1990. The frequency of unrecognized type 2 herpes simplex virus infection among women: implications for the control of genital herpes. Sex. Transm. Dis. 17:90-94.
34. Kulhanjian, J. A., V. Soroush, D. S. Au, R. N. Bronzan, L. L. Yasukawa, L. E. Weylman, A. M. Arvin, and C. G. Prober. 1992. Identification of women at unsuspected risk of primary infection with herpes simplex virus type 2 during pregnancy. N. Engl. J. Med. 326:916-920.
35. Leach, C. T., R. L. Ashley, J. Baillargeon, and H. B. Jenson. 2002. Performance of two commercial glycoprotein G-based enzyme immunoassays for detecting antibodies to herpes simplex viruses 1 and 2 in children and young adolescents. Clin. Diagn. Lab. Immunol. 9:1124-1125.
36. Levi, M., U. Ruden, H. Carlberg, and B. Wahren. 1999. The use of peptides from glycoproteins G-2 and D-1 for detecting herpes simplex virus type 2 and type-common antibodies. J. Clin. Virol. 12:243-252.
37. Liljeqvist, J. Å., B. Svennerholm, and T. Bergström. 1999. Herpes simplex virus type 2 glycoprotein G-negative clinical isolates are generated by single frameshift mutations. J. Virol. 73:9796-9802.
38. Liljeqvist, J. Å., E. Trybala, B. Svennerholm, S. Jeansson, E. Sjogren-Jannson, and T. Bergström. 1998. Localization of type-specific epitopes of herpes simplex virus type 2 glycoprotein G recognized by human and mouse antibodies. J. Gen. Virol. 79:1215-1224.
39. Luo, J. H., C. C. Smith, M. Kulka, and L. Aurelian. 1991. A truncated protein kinase domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) expressed in Escherichia coli. J. Biol. Chem. 266:20976-20983.
40. Marsden, H. S., K. MacAulay, J. Murray, and I. W. Smith. 1998. Identification of an immunodominant sequential epitope in glycoprotein G of herpes simplex virus type 2 that is useful for serotype-specific diagnosis. J. Med. Virol. 56:79-84.
41. Martins, T. B., R. D. Woolstenhulme, T. D. Jaskowski, H. R. Hill, and C. M. Litmin. 2001. Comparison of four enzyme immunoassays with a Western blot assay for the determination of type-specific antibodies to herpes simplex virus. Am. J. Clin. Pathol. 115:272-277.
42. Nikas, I., J. McLauchlan, A. J. Davison, W. R. Taylor, and J. B. Clements. 1986. Structural features of ribonucleotide reductase. Proteins Struct. Funct. Genet. 1:376-384.
43. Oladepo, D. K., P. E. Klapper, and H. S. Marsden. 2000. Peptide based enzyme-linked immunoassays for detection of anti-HSV-2 IgG in human sera. J. Virol. Methods 87:63-70.
44. Peng, T., J. R. C. Hunter, and J. W. Nelson. 1996. The novel protein kinase and the RR1 subunit of herpes simplex virus has autophosphorylation and transphosphorylation activity that differs in its ATP requirements for HSV-1 and HSV-2. Virology 216:184-196.
45. Perkins, D., E. F. R. Pereira, and L. Aurelian. 2003. The herpes simplex virus type 2 R1 protein kinase (1CP10 PK) functions as a dominant regulator of apoptosis in hippocampal neurons by activating the ERK survival pathway and upregulating the antiapoptotic protein Bag-1. J. Virol. 77:1292-1305.
46. Prince, H. E., C. E. Ernst, and W. R. Hogrefe. 2000. Evaluation of an enzyme immunoassay system for measuring herpes simplex virus (HSV) type 1-specific and HSV type 2-specific IgG antibodies. J. Clin. Lab. Anal. 14:13-16.
47. Rekahdar, E., P. Tunback, J. A. Liljeqvist, and T. Bergstrom. 1999. Variability of the glycoprotein G gene in clinical isolates of herpes simplex virus type 1. Clin. Diagn. Lab. Immunol. 6:826-831.
48. Rekabdar, E., P. Tunback, J.-A. Liljeqvist, M. Lindh, and T. Bergstrom. 2002. Dichotomy of glycoprotein G gene in herpes simplex virus type 1 isolates. J. Clin. Microbiol. 40:3245-3251.
49. Renzi, C., J. M. Douglas, Jr., M. Foster, C. W. Critchlow, R. Ashley-Morrow, S. P. Buchbinder, B. A. Koblin, D. J. McKirnan, K. H. Mayer, and C. L. Celum. 2003. Herpes simplex virus type 2 infection as a risk factor for human immunodeficiency virus acquisition in men who have sex with men. J. Infect. Dis. 187:19-25.
50. Safrin, S., A. Arvin, J. Mills, and R. Ashley. 1992. Comparison of the Western immunoblot assay and a glycoprotein G enzyme immunoassay for detection of serum antibodies to herpes simplex virus type 2 in patients with AIDS. J. Clin. Microbiol. 30:1312-1314.
51. Samarai, A., A. Shareef, G. Kinghorn, and C. Potter. 1989. Sequential genital infections with herpes simplex virus types 1 and 2. Genitourin. Med. 65:39-41.
52. Sánchez-Martínez, D., D. S. Schmid, W. Whittington, D. Brown, W. C. Reeves, S. Chatterjee, R. J. Whitley, and P. E. Pellett. 1991. Evaluation of a test based on baculovirus-expressed glycoprotein G for detection of herpes simplex virus type-specific antibodies. J. Infect. Dis. 164:1196-1199.
53. Sauerbrei, A., U. Eichhorn, G. Hottenrott, and P. Wutzler. 2000. Virological diagnosis of herpes simplex encephalitis. J. Clin. Virol. 17:31-36.
54. Saville, M., D. Brown, C. Burgess, K. Perry, S. Barton, F. Cowan, G. Palu, and C. Mengoli. 2000. An evaluation of near patient tests for detecting herpes simplex virus type-2 antibody. Sex. Transm. Infect. 76:381-382.
55. Schmid, D. S., D. R. Brown, R. Nisenbaum, R. L. Burke, D. Alexander, R. Ashley, P. E. Pellett, and W. C. Reeves. 1999. Limits in reliability of glycoprotein G-based type-specific serologic assays for herpes simplex virus types 1 and 2. J. Clin. Microbiol. 37:376-379.
56. Smith, C. C., J. Nelson, L. Aurelian, M. Gober, and B. B. Goswami. 2000. Ras-GAP binding and phosphorylation by herpes simplex virus type 2 RR1 PK (ICP10 PK) and activation of the Ras/MEK/MAPK mitogenic pathway are required for timely onset of virus growth. J. Virol. 74:10417-10429.
57. Smith, C. C., T. Peng, M. Kulka, and L. Aurelian. 1998. The PK domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is involved in IE gene transcription and virus growth. J. Virol. 72:9131-9141.
58. Smith, J. S., and N. J. Robinson. 2002. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J. Infect. Dis. 186:S3-S28.
59. Svennerholm, B., S. Olofsson, S. Jeansson, A. Vahlne, and E. Lycke. 1984. Herpes simplex virus type-selective enzyme linked immunosorbent assay with Helix pomatia lectin-purified antigens. J. Clin. Microbiol. 19:235-239.
60. Wachsman, M., M. Kulka, C. C. Smith, and L. Aurelian. 2001. A growth and latency defective herpes simplex virus type 2 mutant (ICP10ΔPK) has prophylactic and therapeutic protective activity in guinea pigs. Vaccine 19:1879-1890.
61. Wald, A., L. Corey, R. Cone, A. Hobson, G. Davis, and J. Zeh. 1997. Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. J. Clin. Investig. 99:1092-1097.
62. Whitley, R. J., and F. Lakeman. 1995. Herpes simplex virus infections of the central nervous system: therapeutic and diagnostic considerations. Clin. Infect. Dis. 20:414-420.
63. Whittingon, W. L., C. L. Celum, A. Cent, and R. L. Ashley. 2001. Use of a glycoprotein G-based type specific assay to detect antibodies to herpes simplex virus type 2 among persons attending sexually transmitted clinics. Sex. Transm. Dis. 28:99-104.
64. Wutzler, P., H. W. Doerr, I. Färber, U. Eichhorn, B. Helbig, A. Sauerbrei, A. Brandstädt, and H. F. Rabenau. 2000. Seroprevalence of herpes simplex virus type 1 and type 2 in selected German populations-relevance for the incidence of genital herpes. J. Med. Virol. 61:201-207.
65. Xu, F., J. A. Schillinger, M. R. Sternberg, R. E. Johnson, F. K. Lee, A. J. Nahmias, and L. E. Markowitz. 2002. Seroprevalence and coinfection with herpes simplex virus type 1 and type 2 in the United States, 1988-1994. J. Infect. Dis. 185:1019-1024.